Latest News

(UroToday.com) Immune checkpoint inhibitors (ICIs) such as atezolizumab (PD-L1), are considered standard therapy for patients with metastatic urothelial carcinoma (mUC) that has progressed after first-line platinum-based chemotherapy. However, only close to 20% of patients will derive sustained benefit from ICI treatment. Therefore, it is critical to find factors associated with the enhanced efficacy of ICIs in […]

(UroToday.com) Von-Hippel Lindau (VHL) disease is an autosomal dominant hereditary disorder, which harbors an increased risk of developing renal cell carcinoma (RCC), CNS, and retinal hemangioblastomas, pancreatic neuroendocrine tumors, and other lesions. RCC occurs in 25-60% of individuals and is a key cause of morbidity and mortality. Surgery is generally considered when the largest renal tumor […]

(UroToday.com)  Dr. Juergen Gschwend summarized the three important abstracts in the setting of metastatic urothelial carcinoma (mUC) that were presented at the European Society of Medical Oncology (ESMO) 2020 Virtual Congress: LBA24 – TROPHY-U-01 Cohort 1 Final Results: A Phase 2 Study of Sacituzumab Govitecan (SG) in Metastatic Urothelial Cancer (mUC) That Has Progressed After Platinum […]

(UroToday.com) In this presentation, Dr. Richard Cathomas summarized both abstracts LBA23 – (pembrolizumab combined with chemotherapy vs. chemotherapy alone as first-line therapy for advanced urothelial carcinoma: KEYNOTE-361), and abstract 697 – (phase 3, randomized, open-label study of the first-line durvalumab with or without tremelimumab vs. standard of care chemotherapy in patients with unresectable, locally advanced or […]

(UroToday.com) Aristotelis Bamias, MD, presented the IMvigor 130 study which was a global phase 3 multicenter, randomized, placebo-controlled trial. The trial evaluated atezolizumab with and without platinum-based chemotherapy in patients with locally advanced or metastatic urothelial carcinoma (mUC), who had no prior systemic therapy in the metastatic setting. The study design is shown in figure 1, […]

Catheter-associated urinary tract infections (CAUTIs) occur frequently in pediatric inpatients, and they are associated with increased morbidity and cost. Few studies have investigated ambulatory CAUTIs, despite at-risk children utilizing home urinary catheterization.

To develop and validate a model to predict 12-month continence status after robot assisted radical prostatectomy (RARP) from preoperative and 3-month postoperative data; this model could help in informing patients on their individualized risk of urinary incontinence (UI) after radical prostatectomy in order to choose the best treatment option.

To compare the health literacy (HL) of the adult females with SUI complaints in terms of their acceptance or non-acceptance of surgery. In this cohort study, the European Health Literacy Survey Questionnaire (HLS-EU- Q47) scores as a measure of health literacy were compared among the two groups of patients who accepted to undergo surgery for […]

Postoperative urinary retention (PUR) is a known complication of midurethral sling (MUS) placement. The use of certain perioperative medications may influence the risk of this complication. This study aimed to investigate the association of perioperative medications with urinary retention after MUS.

To examine the association of race/ethnicity with urinary incontinence subtypes and overactive bladder and associated bother in older men. This cross-sectional analysis utilized data from Multi-Ethnic Study of Atherosclerosis, an observational cohort of four racial/ethnic groups.